All relevant data are within the paper and its Supporting Information files.

Introduction {#sec001}
============

Phenotypic similarity plays an important role in different biological and biomedical applications. Previous studies prove that genes with similar phenotypes yields biological modules in terms of diseases, thus it can be used in predicting disease-causing genes \[[@pone.0115692.ref001]\]\[[@pone.0115692.ref002]\]. Furthermore, it is crucial for understanding the relationships between different diseases \[[@pone.0115692.ref003]\].

Most current methods for measuring phenotypic similarity \[[@pone.0115692.ref004]\]\[[@pone.0115692.ref005]\] are based on the Online Mendelian Inheritance in Man (OMIM) database \[[@pone.0115692.ref006]\] that contains textual records representing genetic disorders. However, the absence of a controlled vocabulary makes it difficult to analyze the OMIM data using a computational approach \[[@pone.0115692.ref007]\]. The Human phenotype ontology (HPO) \[[@pone.0115692.ref008]\] provides a controlled and standardized vocabulary of phenotypic abnormalities annotating all clinical entries in OMIM, which sheds light on the large-scale computational analysis of the human phenome, i.e., DECIPHER \[[@pone.0115692.ref009]\], ECARUCA \[[@pone.0115692.ref010]\] and Bridge \[[@pone.0115692.ref011]\].

Several tools using HPO-based semantic similarity are currently available. Phenomizer \[[@pone.0115692.ref012]\] is the first tool for semantic similarity search over HPO, in which users input the phenotypic abnormalities of a patient as HPO IDs, and obtain a list of diagnoses in OMIM IDs. Other tools include OwlSim \[[@pone.0115692.ref013]\], PhenoDigm \[[@pone.0115692.ref014]\], PhenomeNET/PhenomeBrowser \[[@pone.0115692.ref015]\] and OntoSIML \[[@pone.0115692.ref016]\]. The detailed comparison of HPOSim and other HPO-based tools is shown in [Table 1](#pone.0115692.t001){ref-type="table"}. It can be seen from the table that most of the existing tools share one drawback: the calculations of phenotypic similarity for HPO terms, genes and diseases are not well supported. Although OntoSIML and OwlSim provide functions for calculating semantic similarity, users are required to manually input the mapping from entities (gene or disease) to HPO terms, which entails additional preprocessing effort.

10.1371/journal.pone.0115692.t001

###### Comparison of HPOSim and other HPO-based tools.

![](pone.0115692.t001){#pone.0115692.t001g}

  **Name**                                                                   **Release Type**     **Open Source**   **Term-Term Similarity**   **Gene-Gene Similarity**                 **Disease-Disease Similarity**   **Gene-Disease Similarity**              **Similarity Measures**                                                          **Combine Methods**
  -------------------------------------------------------------------------- -------------------- ----------------- -------------------------- ---------------------------------------- -------------------------------- ---------------------------------------- -------------------------------------------------------------------------------- --------------------------------------
  HPOSim                                                                     Stand Alone (R)      √                 √                          √                                        √                                ×                                        Resnik, Lin, Jiang-Conrath, relevance, information coefficient, graph IC, Wang   Max, Mean, funSimMax, funSimAvg, BMA
  Phenomizer \[[@pone.0115692.ref012]\]                                      Web                  ×                 ×                          ×                                        ×                                √                                        Resnik                                                                           symmetric, unsymmetric
  OWLSim \[[@pone.0115692.ref013]\][\#](#t001fn002){ref-type="table-fn"}     Stand Alone (Java)   √                 √                          √                                        √                                √                                        Jaccard, Resnik, overlap/normalized overlap, GIC                                 Max, Mean, BMA
  PhenoDigm \[[@pone.0115692.ref014]\]                                       Web                  ×                 ×                          ×                                        ×                                √                                        Mean of Jaccard and Resnik                                                       Max, Mean
  PhenomeNET \[[@pone.0115692.ref015]\]                                      Web                  ×                 ×                          √[\*](#t001fn001){ref-type="table-fn"}   √                                √[\*](#t001fn001){ref-type="table-fn"}   simGIC                                                                           Unknown
  OntoSIML \[[@pone.0115692.ref016]\][\#](#t001fn002){ref-type="table-fn"}   Web                  ×                 √                          √                                        √                                √                                        Jaccard, simGIC, Resnik                                                          Unknown

\* PhenomeNET only supports human genes included in OMIM.

\# Although OntoSIML and OwlSim provide functions for calculating semantic similarity, users are required to manually input the mapping from entities (gene or disease) to HPO terms, which entails additional preprocessing effort.

"√" means the tool provides the function and "×" means the tool does not.

In addition, there exist several tools for HPO-based enrichment analysis. OntoFUNC \[[@pone.0115692.ref017]\] performs functional enrichment analysis over ontologies in OWL format. It is based on FUNC \[[@pone.0115692.ref018]\] and users need to manually input the mapping data, which is the same as OntoSIML. STOP \[[@pone.0115692.ref019]\] is an online tool and can be used as a Cytoscape plug-in. It can be used in the enrichment analysis of gene sets, but does not support the analysis of disease set.

Several R packages for semantic similarity and enrichment analysis are available, including GOSim \[[@pone.0115692.ref020]\], GOSemSim \[[@pone.0115692.ref021]\], DOSim \[[@pone.0115692.ref022]\], DOSE \[[@pone.0115692.ref023]\] and topGO \[[@pone.0115692.ref024]\]. However, these packages mainly use gene ontology (GO) \[[@pone.0115692.ref025]\] and disease ontology (DO) \[[@pone.0115692.ref026]\]. To the best of our knowledge, there is no R package that focuses on HPO-based semantic similarity and enrichment analysis.

Thus, we developed an R package HPOSim with an immediate purpose to capturing phenotypic similarities between genes and diseases. The framework of HPOSim is shown in [Fig. 1](#pone.0115692.g001){ref-type="fig"}. HPOSim analyzes semantic similarity for HPO terms, genes and diseases. Functional enrichment analysis of gene set and disease set are also provided, including the classic hypergeometric enrichment analysis and the novel network ontology analysis (NOA) \[[@pone.0115692.ref027]\].

![Framework of HPOSim.\
Users can use HPOSim to calculate semantic similarity for HPO terms, genes and diseases. HPOSim can also be used to identify enriched HPO terms for gene set and disease set.](pone.0115692.g001){#pone.0115692.g001}

Implementation {#sec002}
==============

Data {#sec002a}
----

HPO contains over 10000 terms (10686 terms in the HPO build \#1042 released in September 2014) in three sub-ontologies, which are phenotypic abnormality (PA), onset and clinical course (OC) and mode of inheritance (MI). Approximately 99% of the HPO terms are in the PA sub-ontology. In each sub-ontology, terms are arranged in a directed acyclic graph (DAG) and are related to their parent terms by "is a" relationships. The structure of the HPO allows a term to have multiple parent terms, which enables different aspects of phenotypic abnormalities to be explored. Diseases and genes are annotated to the most specific terms possible, which means that if a disease or a gene is annotated to a term then all of the ancestors of this term also apply (see [Fig. 2](#pone.0115692.g002){ref-type="fig"} for an example).

![Example of the structure of HPO.\
HPO term *Abnormality of the joints of the lower limbs* (HP:0100491) and all its ancestor terms are shown. Each term in the HPO describes a phenotypic abnormality. Terms are related to parent terms by "is a" relationships in the form of a directed acyclic graph. If a disease or a gene is annotated to a term, it will also be annotated to all of its ancestors.](pone.0115692.g002){#pone.0115692.g002}

The official ontology file provided by the HPO Consortium is in obo format, which is plain text-based. Thus, like other widely used R package for biomedical ontologies, e.g. GO.db, we constructed an R package termed HPO.db. HPO.db provided programmatic interfaces to the hierarchical structure of HPO terms. HPOSim uses HPO.db to obtain information about terms and relationships between terms. HPO.db can be used by other R packages that use HPO data.

HPOSim provides two kinds of pre-calculated data within the package: the association between HPO terms, as well as association between genes and diseases (gene-to-phenotype, phenotype-to-gene, disease-to-phenotype and phenotype-to-disease). The associations between HPO terms are obtained from the original ontology and annotation data provided by the HPO Consortium, and the information content (IC) of the HPO terms is pre-calculated based on both genes and diseases annotated to a certain term, while semantic similarity between genes and diseases are based on the IC of HPO terms.

The IC of a term *t* in HPO can be defined as follows:
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where *p*(*t*) is the probability of observing *t* and its descendants in all genes/diseases annotated to a certain sub-ontology of HPO.

Measuring the similarity between HPO terms {#sec002b}
------------------------------------------

Recently, several metrics that measure the semantic similarity between ontology annotations have been proposed \[[@pone.0115692.ref028]\]. In HPOSim, we implement seven commonly used semantic similarity measures to measure the similarity between HPO terms: the Resnik measure \[[@pone.0115692.ref029]\], Lin measure \[[@pone.0115692.ref030]\], Jiang--Conrath measure \[[@pone.0115692.ref031]\], relevance measure \[[@pone.0115692.ref032]\], information coefficient measure \[[@pone.0115692.ref033]\], graph IC measure \[[@pone.0115692.ref034]\] and Wang measure \[[@pone.0115692.ref035]\]. The first six measures are based on IC, while the Wang measure uses both IC and graph structure.

The Resnik measure defines the similarity between terms as the IC of their most informative common ancestor (MICA):
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where *t~MICA~* is the MICA of term *t~1~* and *t~2~*.

The Lin and Jiang--Conrath measures consider the IC of the two terms besides the IC of their MICA:
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The relevance measure and the information coefficient measure are based on Lin's measure:
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The graph IC measure takes all the common ancestors of the two terms into account:
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where *A*(*t*) is the ancestors of term t in HPO.

The Wang measure is based on the graph structure of HPO DAG. In Wang's measure, a weight is given to each edge according to its type. *DAG~t~* = (*t*,*T~t~*,*E~t~*) represents the subgraph made up of term *t* and its ancestors, where *T~t~* is the set of the ancestor terms of *t* and *E~t~* is the set of edges in *DAG~t~*.

In *DAG~t~*, *S~t~*(*n*) measures the semantic contribution of term *n* to term *t*, which is defined as:
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The similarity between HPO term *t~1~* and term*t~2~* is defined as:
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where *SV*(*m*) is the sum of the semantic contributions of all the terms in *DAG~m~*.

Combining term-term similarity into gene-gene and disease-disease similarity {#sec002c}
----------------------------------------------------------------------------

In HPOSim, the similarity between two genes is calculated based on the pairwise similarity of the two HPO term sets annotating these two genes. HPOSim provides five methods to combine multiple term-term similarities into one gene-gene similarity, which are "Max" \[[@pone.0115692.ref036]\], "Mean" \[[@pone.0115692.ref036]\], "funSimMax" \[[@pone.0115692.ref032]\], "funSimAvg" \[[@pone.0115692.ref032]\], and "BMA" \[[@pone.0115692.ref035]\].

Given gene *g~1~* annotated by HPO term set *HPO~1~* = {*t~11~*, *t~12~*,...,*t~1m~*} and *g~2~* annotated by *HPO~2~* = {*t~21~*, *t~22~*,...,*t~2n~*}. The similarity matrix *S*=\[*s~i\ j~*\]~*m*×*n*~ contains all pairwise similarity scores of terms in *HPO~1~* and *HPO~2~*.

The "Max" method calculates the maximum semantic similarity score over all pairs of HPO terms in the two term sets, and is defined as follows.
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The "Mean" method calculates the average semantic similarity score over all pairs of HPO terms in the two term sets, and is defined as follows.

![](pone.0115692.e011.jpg){#pone.0115692.e011g}

S

i

m

M

e

a

n

(

g

1

,

g

2

)

=

1

m

×

n

∑

i

=

1

m

∑

j

=

1

n

s

i

j

The "funSimMax", "funSimAvg" and "BMA" methods are based on the maximum value in each row and column of similarity matrix *S*.

The "funSimMax" and "funSimAvg" methods \[[@pone.0115692.ref032]\] use the arithmetic maxima and average between similarities for two directional comparisons of the similarity matrix *S*.
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The "BMA" method uses the best-match average strategy, which calculates the average of all maximum similarities on each row and column of the similarity matrix *S*.
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The calculation of the similarity between diseases is the same as that between genes. The similarity between two diseases is calculated based on the pairwise similarity of the two term sets annotating these two diseases.

HPO-based Enrichment Analysis {#sec002d}
-----------------------------

HPOSim provides HPO-based enrichment analysis to investigate the phenotypic features of gene sets or disease sets. Two enrichment analysis methods are provided: hypergeometric test and the NOA method \[[@pone.0115692.ref027]\].

Given an HPO term *t* and a gene set with *T* genes, assuming that there are *R* genes/diseases annotated in the whole HPO in which *G* genes/diseases are annotated to *t*. In addition, there are *O* genes/diseases in the gene set that are annotated to *t*. The hypergeometric enrichment p-value for *t* is calculated as follows:
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In NOA, users input a gene or disease network. For each edge in the network, the HPO terms annotating this edge are defined as the intersection of the two term sets annotating the two nodes of the edge. NOA uses HPO terms annotating the edges to perform the enrichment analysis. Two alternative strategies, "sub-net" and "whole-net", are applied to choose the reference set. In the "sub-net" strategy, users are required to provide the reference set. While in the "whole-net" strategy, the complete graph on the nodes of the input network is used as the reference set.

Results and Discussion {#sec003}
======================

HPOSim consists of two parts: (i) the similarity measures between phenotypes (HPO terms), between human genes (Entrez IDs) and between diseases (OMIM IDs), and (ii) HPO-based enrichment analysis (NOA and the hypergeometric method) for gene set and disease set.

Application on gene similarity and gene set enrichment analysis {#sec003a}
---------------------------------------------------------------

We used the aging network \[[@pone.0115692.ref037]\] to demonstrate the application of gene semantic similarity provided by HPOSim. The aging network was constructed by identifying genes related to aging and adding edges between interacting gene pairs. After removing the genes that are not annotated in the PA sub-ontology of HPO, 102 genes and 293 interactions were remained (see [S1 Dataset](#pone.0115692.s001){ref-type="supplementary-material"} for detail).

First, the semantic similarity matrix of the 102 genes was constructed using the Resnik measure and "funSimMax" combining method (see [S2 Dataset](#pone.0115692.s002){ref-type="supplementary-material"} for detail). A hierarchical clustering was then performed using the R package stats, and six modules were detected using the R package dynamicTreeCut. HPO enrichment analysis (hypergeometric test) was then performed using HPOSim. GO enrichment analysis and pathway enrichment analysis based on KEGG (Kyoto Encyclopedia of Genes and Genomes) pathway database \[[@pone.0115692.ref038]\] were performed using DAVID \[[@pone.0115692.ref039]\]. The results are shown in [Table 2](#pone.0115692.t002){ref-type="table"}.

10.1371/journal.pone.0115692.t002

###### Gene modules of the aging network.

![](pone.0115692.t002){#pone.0115692.t002g}

  **Module**   **Size**   **Genes (Entrez ID)**                                                                                                                                                                       **TOP 5 Enriched GO BP Terms**                                                                                                                                                            **TOP 5 Enriched HPO Terms**                                                                                                                                                               **TOP 5 Enriched KEGG Pathways**
  ------------ ---------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  M1           36         25, 207, 472, 581, 596, 641, 672, 675, 701, 1029, 1050, 1499, 1956, 2064, 2308, 3265, 4193, 4292, 4609, 5159, 5422, 5728, 5781, 5925, 6794, 7015, 7157, 7486, 9184, 1385, 7153, 627, 1649   regulation of apoptosis, cell cycle process, regulation of programmed cell death, regulation of cell death, regulation of cell cycle                                                      Neoplasm, Neoplasm by anatomical site, Neoplasm by histology, Sarcoma, Hematological neoplasm                                                                                              Pathways in cancer, Prostate cancer, Endometrial cancer, Glioma, Bladder cancer
  M2           26         545, 1387, 2010, 2033, 2068, 2073, 2074, 2260, 3479, 3480, 4000, 4036, 4792, 4803, 5979, 7020, 7314, 7341, 7415, 7507, 5830, 1950, 1161, 847, 1490, 2067                                    DNA metabolic process, response to UV, response to radiation, DNA repair, nucleotide-excision repair                                                                                      Intrauterine growth retardation, Aplasia/Hypoplasia of the mandible, Micrognathia, Defective DNA repair after ultraviolet radiation damage, Abnormality of the mandible                    Nucleotide excision repair, Prostate cancer, Pathways in cancer, Melanoma, Adherens junction
  M3           17         367, 2099, 2353, 2690, 2908, 3630, 3643, 3952, 3953, 5449, 5578, 6777, 7040, 8626, 8820, 2688, 5626                                                                                         response to hormone stimulus, response to endogenous stimulus, response to organic substance, positive regulation of macromolecule metabolic process, response to estrogen stimulus       Abnormality of the anterior pituitary, Abnormality of the pituitary gland, Abnormality of the endocrine system, Abnormality of the hypothalamus-pituitary axis, Anterior hypopituitarism   Jak-STAT signaling pathway, Neuroactive ligand-receptor interaction, Cytokine-cytokine receptor interaction, Aldosterone-regulated sodium reabsorption, Pathways in cancer
  M4           11         355, 2071, 3561, 3575, 4683, 4791, 5295, 5580, 6774, 6929, 5336                                                                                                                             cell activation, B cell activation, lymphocyte activation, leukocyte activation, immune system development                                                                                Abnormality of lymphocytes, Abnormal immunoglobulin level, Abnormality of B cell physiology, Abnormality of B cells, Abnormality of humoral immunity                                       Pathways in cancer, Jak-STAT signaling pathway, Fc epsilon RI signaling pathway, Fc gamma R-mediated phagocytosis, Neurotrophin signaling pathway
  M5           9          3064, 4001, 4137, 5155, 6872, 6908, 5663, 6647, 1938                                                                                                                                        negative regulation of neuron apoptosis, regulation of neuron apoptosis, positive regulation of MAP kinase activity, behavior, regulation of membrane potential                           Abnormality of extrapyramidal motor function, Personality changes, Adult onset, Dysarthria, Parkinsonism                                                                                   Huntington's disease, Basal transcription factors
  M6           5          348, 351, 3717, 2876, 5328                                                                                                                                                                  regulation of response to external stimulus, induction of apoptosis, induction of programmed cell death, positive regulation of apoptosis, positive regulation of programmed cell death   Long-tract signs, Abnormal bleeding, Abnormalities of the peripheral arteries, Arterial stenosis, Cerebral inclusion bodies                                                                N/A[\*](#t002fn001){ref-type="table-fn"}

\* N/A indicates that there are no enriched KEGG pathway (p-value\<0.05) for this module.

Module M5 only have two enriched KEGG pathway (p-value\<0.05).

Gene FOXO4 (Entrez ID: 4303) could not be grouped into a certain module.

It can be seen that the enriched GO and HPO annotations are largely different among these modules. For example, the enriched GO annotations of module M2 implied that aging is associated with radiation including ultraviolet (UV), which has been verified by previous study in skin aging \[[@pone.0115692.ref040]\]. While the enriched GO annotations of module M3 implied that aging is associated with hormone stimulus, and literature mining showed that older women require a greater parathyroid hormone stimulus than younger women \[[@pone.0115692.ref041]\]. The enriched HPO annotations of the module M3 implied that aging are associated with abnormality of the pituitary, which has been verified by Sano *et al*. \[[@pone.0115692.ref042]\]. Disease enrichment analysis based on OMIM was then performed on genes in M3 using DAVID \[[@pone.0115692.ref039]\] and showed that term "Pituitary hormone deficiency, combined" was representative (p-value = 8.2E-3).

The enriched pathways of different modules are closely related to cancer, however various among different modules. Jak-STAT signaling pathway was found to be representative in modules M3 and M4. In a previous study by Fulop *et al*. \[[@pone.0115692.ref043]\], it was found that the signalling of IL-2 receptors is altered in T cells and macrophages with aging, mainly in relation to the Jak-STAT pathway.

These results above indicate that HPO-based semantic similarity can provide a different aspect in disease-related studies other than GO.

NOA and hypergeometric gene set enrichment analysis were then performed on the aging network. The "whole-net" strategy \[[@pone.0115692.ref027]\] was used to choose the reference set in NOA. The top 10 enriched HPO terms in the two enrichment methods are shown in [Table 3](#pone.0115692.t003){ref-type="table"}. It can be seen that both enrichment methods identify neoplasm-related HPO terms as the top hits. However, these two methods give different terms and different ranks of terms. When dealing with gene/disease sets from biological networks, users are suggested to use the NOA method. If the gene sets are not from network data, users can use either hypergeometric or NOA enrichment method.

10.1371/journal.pone.0115692.t003

###### Top 10 enriched HPO terms by the NOA method and hypergeometric enrichment.

![](pone.0115692.t003){#pone.0115692.t003g}

  **Rank**   **NOA(whole-net)**   **Hypergeometric Enrichment**                                                                                
  ---------- -------------------- ------------------------------------------ --------- ------------ ------------------------------------------ ---------
  1          HP:0011793           Neoplasm by anatomical site                \<1E-14   HP:0002664   Neoplasm                                   \<1E-14
  2          HP:0002664           Neoplasm                                   4.8E-14   HP:0011792   Neoplasm by histology                      1.2E-13
  3          HP:0007379           Neoplasm of the genitourinary tract        1.6E-5    HP:0011793   Neoplasm by anatomical site                1.1E-12
  4          HP:0001156           Brachydactyly syndrome                     4E-5      HP:0100242   Sarcoma                                    3.1E-10
  5          HP:0010787           Genital neoplasm                           5.1E-5    HP:0004377   Hematological neoplasm                     6.9E-8
  6          HP:0008069           Neoplasm of the skin                       5.7E-4    HP:0000008   Abnormality of female internal genitalia   7.7E-7
  7          HP:0001909           Leukemia                                   3.6E-3    HP:0004375   Neoplasm of the nervous system             7.7E-7
  8          HP:0000006           Autosomal dominant inheritance             4.2E-3    HP:0002665   Lymphoma                                   7.7E-7
  9          HP:0000008           Abnormality of female internal genitalia   4.2E-3    HP:0000812   Abnormal internal genitalia                8.2E-7
  10         HP:0000812           Abnormal internal genitalia                4.4E-3    HP:0010460   Abnormality of the female genitalia        8.6E-7

Both enrichment methods identify HPO terms related to neoplasm as the top hits. However, these two methods give different enriched terms and different ranks of terms.

Application on disease similarity and disease set enrichment analysis {#sec003b}
---------------------------------------------------------------------

HPOSim can also be used to investigate the phenotypic relationships between diseases. First, 115 cancer related entries were obtained by searching the OMIM database \[[@pone.0115692.ref006]\] using "cancer" or "carcinoma" as the key word. After removing the diseases that are not annotated in the PA sub-ontology of HPO and all the genes, 55 disease entries were remained (see [S3 Dataset](#pone.0115692.s003){ref-type="supplementary-material"} for detail).

The semantic similarity matrix of the 55 disease entries was constructed using the Resnik measure and "funSimMax" combining method (see [S4 Dataset](#pone.0115692.s004){ref-type="supplementary-material"} for detail). A hierarchical clustering was then performed and four modules were detected using the same routine as used in the previous case study. HPO enrichment analysis (hypergeometric test) was also performed using HPOSim. The results are shown in [Table 4](#pone.0115692.t004){ref-type="table"}.

10.1371/journal.pone.0115692.t004

###### Disease modules of the cancer entries in OMIM.

![](pone.0115692.t004){#pone.0115692.t004g}

  **Module**   **Size**   **Diseases (OMIM ID)**                                                                                                                                                                                                                                                                         **TOP 5 Enriched HPO Terms**
  ------------ ---------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------------------------------------------------------------------------
  M1           22         OMIM:246470, OMIM:114550, OMIM:120435, OMIM:133239, OMIM:137215, OMIM:148500, OMIM:260350, OMIM:276300, OMIM:601228, OMIM:606719, OMIM:608615, OMIM:609310, OMIM:612229, OMIM:612591, OMIM:613244, OMIM:613347, OMIM:613659, OMIM:614331, OMIM:614337, OMIM:614350, OMIM:614385, OMIM:615083   Neoplasm by anatomical site, Neoplasm, Abnormality of the large intestine, Neoplasm of the large intestine, Neoplasm of the gastrointestinal tract
  M2           13         OMIM:109400, OMIM:109800, OMIM:114500, OMIM:144700, OMIM:150800, OMIM:176807, OMIM:273300, OMIM:300854, OMIM:312300, OMIM:601518, OMIM:603688, OMIM:605074, OMIM:608089                                                                                                                        Neoplasm of the genitourinary tract, Neoplasm, Neoplasm by anatomical site, Genital neoplasm, Urinary tract neoplasm
  M3           12         OMIM:603641, OMIM:114480, OMIM:158320, OMIM:167000, OMIM:211980, OMIM:260500, OMIM:275355, OMIM:603956, OMIM:604370, OMIM:612555, OMIM:614456, OMIM:614564                                                                                                                                     Breast carcinoma, Neoplasm, Neoplasm of the breast, Neoplasm by anatomical site, Abnormality of the breast
  M4           6          OMIM:155240, OMIM:171400, OMIM:188470, OMIM:188550, OMIM:202300, OMIM:608266                                                                                                                                                                                                                   Neoplasm of the endocrine system, Thyroid carcinoma, Neoplasm of the thyroid gland, Abnormality of thyroid morphology, Neoplasm by anatomical site

OMIM:191600 (URETER, CANCER OF) and OMIM:610644 (PALMOPLANTAR HYPERKERATOSIS WITH SQUAMOUS CELL CARCINOMA OF SKIN AND 46,XX SEX REVERSAL) could not be grouped into a certain module.

The results showed that these four disease modules had different phenotypic features. For example, module M3 included several types of women-only cancer, including breast cancer (OMIM:114480), breast-ovarian cancer (OMIM:604370, OMIM:612555), ovarian cancer (OMIM:167000) and cervical cancer(OMIM:603956). And lung cancer (OMIM:211980) in M3 was the second most commonly diagnosed types of cancer among women in 2013\[[@pone.0115692.ref044]\].

The result above indicated that HPO-based semantic similarity had potential ability to play an important role in disease classification and other disease-related studies.

Conclusions {#sec004}
===========

HPOSim is an open source R package that contains seven semantic similarity measures and two enrichment analysis based on HPO data. Also, it provides useful functions for disease-related research and can be integrated with other R packages. In future work, we will integrate more similarity measures and other functions, such as visualization of the HPO data.

Supporting Information {#sec005}
======================

###### Aging network after removing the genes that are not annotated in PA sub-ontology of HPO.
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Click here for additional data file.

###### Semantic similarity matrix of the 102 genes in the aging network.

(CSV)
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Click here for additional data file.

###### Cancer entries in OMIM.
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Click here for additional data file.

###### Semantic similarity matrix of the 55 cancer entries.

(CSV)

###### 

Click here for additional data file.
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